Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 1/20 | 0.54 |
| ▸ | USP30 | Q70CQ3 | 5/20 | 0.50 |
| ▸ | RECQL | P46063 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.45 |
| ▸ | PTPN2 | P17706 | 1/20 | 0.44 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.44 |
| ▸ | PTPN6 | P29350 | 1/20 | 0.44 |
| ▸ | JAK2 | O60674 | 1/20 | 0.41 |
| ▸ | JAK1 | P23458 | 1/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
| ▸ | STS | P08842 | 1/20 | 0.41 |
| ▸ | ABL1 | P00519 | 1/20 | 0.41 |
| ▸ | RIN1 | Q13671 | 1/20 | 0.41 |
| ▸ | USP2 | O75604 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL894559 | 1.00 | HPGD (0.54) | HPGDUSP30RECQLKMT2AALDH1A1 | |
| SCHEMBL586312 | 1.00 | HPGD (0.54) | HPGDUSP30RECQLKMT2AALDH1A1 | |
| SCHEMBL442932 | 0.92 | MEN1 (0.56) | HPGDUSP30RECQLKMT2AALDH1A1 | |
| SCHEMBL968401 | 0.92 | MEN1 (0.56) | HPGDUSP30RECQLKMT2AALDH1A1 | |
| SCHEMBL1249710 | 0.92 | MEN1 (0.56) | HPGDUSP30RECQLKMT2AALDH1A1 | |
| SCHEMBL407899 | 0.91 | HPGD (0.56) | HPGDRECQLKMT2AALDH1A1MAPT | |
| SCHEMBL3615534 | 0.91 | HPGD (0.53) | HPGDUSP30RECQLKMT2AALDH1A1 | |
| SCHEMBL278133 | 0.88 | NR1H2 (0.45) | HPGDUSP30RECQLKMT2AALDH1A1 | |
| SCHEMBL2153593 | 0.87 | HPGD (0.57) | HPGDUSP30RECQLKMT2AALDH1A1 | |
| SCHEMBL14348065 | 0.87 | HPGD (0.57) | HPGDUSP30RECQLKMT2AALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 220 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4747256-A1 | PARP1 INHIBITOR COMPOUNDS | Duke Street Bio Limited (GB) | 2026-05-27 | — | — | EP | disclosed |
| US-12552786-B2 | Inhibitors of αvβ6 integrin | MORPHIC THERAPEUTIC, INC. (US) | 2026-02-17 | — | — | US | disclosed |
| EP-4680609-A1 | KRAS MODULATORS AND USES THEREOF | Quanta Therapeutics, Inc. (US) | 2026-01-21 | — | — | EP | disclosed |
| US-12528803-B2 | Inhibitors of αvβ6 integrin | MORPHIC THERAPEUTIC, INC. (US) | 2026-01-20 | — | — | US | disclosed |
| US-20260008789-A1 | KRAS MODULATORS AND USES THEREOF | QUANTA THERAPEUTICS INC (US) | 2026-01-08 | — | — | US | disclosed |
| US-12421254-B2 | KRAS modulators and uses thereof | QUANTA THERAPEUTICS, INC. (US) | 2025-09-23 | — | — | US | disclosed |
| US-20250250261-A1 | NOVEL SUBSTITUTED FLUORINATED VINYL-N-PROPYL-PYRROLIDINE COMPOUNDS, PROCESSES FOR THEIR PREPARATION AND THERAPEUTIC USES THEREOF | SANOFI (FR) | 2025-08-07 | — | — | US | disclosed |
| EP-3843728-B1 | INHIBITORS OF (ALPHA-V)(BETA-6) INTEGRIN | MORPHIC THERAPEUTIC INC (US) | 2025-04-30 | — | — | EP | disclosed |
| WO-2025077671-A1 | POLYSUBSTITUTED ARYL DERIVATIVE AND PREPARATION METHOD THEREFOR AND USE THEREOF | 浙江海正药业股份有限公司 | 2025-04-17 | — | — | WO | disclosed |
| EP-4508032-A1 | NOVEL SUBSTITUTED FLUORINATED VINYL-N-PROPYL-PYRROLIDINE COMPOUNDS, PROCESSES FOR THEIR PREPARATION AND THERAPEUTIC USES THEREOF | Sanofi (FR) | 2025-02-19 | — | — | EP | disclosed |
| US-20080146607-A1 | Heteroaryl pyrrolidinyl and piperidinyl ketone derivatives and uses thereof | ROCHE PALO ALTO LLC | 2008-06-19 | — | — | US | disclosed |
| US-20080146607-A1 | Heteroaryl pyrrolidinyl and piperidinyl ketone derivatives and uses thereof | ROCHE PALO ALTO LLC | 2008-06-19 | — | — | US | disclosed |
| WO-2008011130-A2 | AMIDE COMPOUNDS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2008-01-24 | — | — | WO | disclosed |
| WO-2007146758-A2 | NOVEL MCH RECEPTOR ANTAGONISTS | ELI LILLY AND COMPANY (US) | 2007-12-21 | — | — | WO | disclosed |
| WO-2007146759-A2 | NOVEL MCH RECEPTOR ANTAGONISTS | ELI LILLY AND COMPANY (US) | 2007-12-21 | — | — | WO | disclosed |
| WO-2007117557-A2 | DIAMINOPROPANOL RENIN INHIBITORS | VITAE PHARMACEUTICALS, INC. (US) | 2007-10-18 | — | — | WO | disclosed |
| US-20070219266-A1 | N-Acylated-3-(Benzoyl)-Pyrrolidines as 11-Beta-HSD1 Inhibitors Useful for the Treatment of Metabolic Disorders | ASTRAZENECA AB (SE) | 2007-09-20 | — | — | US | disclosed |
| WO-2007056170-A2 | PYRROLO[2,1-F] [1,2,4] TRIAZIN-4-YLAMINES IGF-1R KINASE INHIBITORS FOR THE TREATMENT OF CANCER AND OTHER HYPERPROLIFERATIVE DISEASES | BAYER HEALTHCARE AG (DE) | 2007-05-18 | — | — | WO | disclosed |
| EP-1685101-A1 | N-ACYLATED-3-(BENZOYL)-PYRROLIDINES AS 11-BETA-HSD1 INHIBITORS USEFUL FOR THE TREATMENT OF METABOLIC DISORDERS. | AstraZeneca AB (SE) | 2006-08-02 | — | — | EP | disclosed |
| WO-2005047250-A1 | N-ACYLATED-3- (BENZOYL) - PYRROLIDINES AS 11-BETA-HSD1 INHIBITORS USEFUL FOR THE TREATMENT OF METABOLIC DISORDERS. | ASTRAZENECA AB (SE) | 2005-05-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070219266-A1 | N-Acylated-3-(Benzoyl)-Pyrrolidines as 11-Beta-HSD1 Inhibitors Useful for the Treatment of Metabolic Disorders | HSD11B1, HSD3B1, HSD17B1 | HPGD 39/4885USP30 1588/4885RECQL 3199/4885 |
| US-20080146607-A1 | Heteroaryl pyrrolidinyl and piperidinyl ketone derivatives and uses thereof | CNKSR1, RB1, AR | HPGD 1370/4885USP30 3288/4885RECQL 490/4885 |
| US-20260008789-A1 | KRAS MODULATORS AND USES THEREOF | KRAS, NRAS, HRAS | HPGD 2973/4885USP30 1468/4885RECQL 311/4885 |
| US-12552786-B2 | Inhibitors of αvβ6 integrin | ITGB6, ITGB1, ITGA6 | HPGD 3206/4885USP30 4721/4885RECQL 4840/4885 |
| US-12421254-B2 | KRAS modulators and uses thereof | KRAS, NRAS, HRAS | HPGD 1514/4885USP30 2549/4885RECQL 620/4885 |
| US-20250250261-A1 | NOVEL SUBSTITUTED FLUORINATED VINYL-N-PROPYL-PYRROLIDINE COMPOUNDS, PROCESSES FOR THEIR PREPARATION AND THERAPEUTIC USES THEREOF | FSHR, GPER1, ESRRA | HPGD 1103/4885USP30 2040/4885RECQL 3572/4885 |
| US-12528803-B2 | Inhibitors of αvβ6 integrin | ITGB2, ITGB6, ITGA2 | HPGD 3944/4885USP30 4848/4885RECQL 4696/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.